CyclinD1, a prominent prognostic marker for endometrial diseases
© Liang et al.; licensee BioMed Central Ltd. 2013
Received: 21 March 2013
Accepted: 29 July 2013
Published: 15 August 2013
Alteration of CyclinD1 was suggested to relate with development of endometrial carcinogenesis before, however CyclinD1 expression is not well defined in endometrial hyperplasia lesions. We checked the relationship between its expression and clinic-pathological variables of endometrial lesions to explore the possibility for CyclinD1 as a potential diagnostic and prognostic marker.
Cyclin D1 immunohistochemical analysis (IHC) was used to evaluate 201 fixed, paraffin-embedded endometrial samples which included simple hyperplasia (n = 27), atypical complex hyperplasia (ACH) (n = 41), endometrioid carcinoma (n = 103), endometrial serous carcinoma (ESC) (n = 21) and clear cell carcinoma (CCC) (n = 9). A breast cancer with known CyclinD1 expression was selected as a positive control in each immunohistochemistry run. We also performed follow-up study to estimate patients’ prognosis.
CyclinD1 was significantly overexpressed in atypical complex hyperplasia (ACH), endometrioid carcinoma and clear cell carcinoma (CCC). The positive signaling of CyclinD1 was showed less than 40% in simple hyperplasia and endometrial serous carcinoma (ESC). The high expression of CyclinD1 was observed in metastasis carcinoma group more significantly than non-metastasis carcinoma group. Kaplan Meier analysis demonstrated that patients with high CyclinD1 expression had an obviously poor prognosis than patients without CyclinD1 staining (p < 0.05). Moreover, according to multivariate Cox regression analysis, CyclinD1 expression, as crucial as metastasis, was a risk marker for overall survival rate.
CyclinD1 exhibited a promising potential to predict the prognosis of patients with endometrial carcinoma. However, the statistical analysis demonstrated that CyclinD1 exhibited a poor ability to differentiate neoplastic lesions from non-neoplastic lesions; thus, the application of CyclinD1 only is not so credible for differentiation between benign and malignant lesions.
The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1871063048950173.
KeywordsEndometrial cancer CyclinD1 Prognostic markers Survival analysis
Endometrial cancer is the most common malignancy of the female genital tract in the world and the seventh most common cause of death for women in Western Europe who suffer from cancer. Every year 7406 new cases are registered in the UK, 88 068 in the European Union and 40 102 in North America. Even though the routine evaluation of estrogen receptor (ER), progesterone receptor (PR) and P53 expression in endometrial cancers are widely used, corpus uteri cancer, lacking new effective prognostic markers, still severely jeopardizes women’s health today. In that case, we are looking forward to some new diagnostic and predict indicators more accurately and credibly.
CyclinD1 (also known as BCL1) which is best known for its utility in mantle cell lymphoma diagnosis is encoded by the CCND1 gene in human beings[2–4]. As a cell -cycle regulator, CyclinD1 is essential for progression through G1 phase and is a candidate proto-oncogene. Mutations, amplification and over-expression of CCND1 gene, which can alters cell cycle progression, are observed frequently in a variety of tumors and may contribute to tumorigenesis[6–9].
In this study, we investigated the expression of CyclinD1 in 5 different pathological types of endometrial diseases, including simple hyperplasia, atypical complex hyperplasia, endometrioid carcinoma, endometrial serous carcinoma and clear cell carcinoma, by immunohistochemistry. We also followed-up the patients and executed survival analysis to explore the possibility of CyclinD1as a diagnostic and prognostic marker for endometrial diseases.
Materials and methods
Different types of endometrial samples were obtained from the Department of Pathology, Qilu Hospital affiliated to Shandong University after getting approval from an Institutional Review Board. Informed consent was obtained from all the patients. All samples were routinely fixed with 10% formaldehyde and embedded with paraffin. Histologic features of all cases were studied with hematoxylin-eosin staining (HE) and diagnosed by two clinical pathologists following established histopathologic criteria of the International Federation of Gynecology Oncology (FIGO)[10, 11]. The samples include simple hyperplasia (n = 27), atypical complex hyperplasia (n = 41), endometrioid carcinoma (n = 103), serous carcinoma (n = 21) and clear cell carcinoma (n = 9). The vast majority of the carcinomas were histologically pure; where mixed, the second component constituted less than 10% of the total tumor volume.
The streptavidin-peroxidase-biotin (SP) immunohistochemical method was performed on the paraffin sections to study the expression of CyclinD1. Briefly, 4-μm-thick paraffin-embedded tissue sections were deparaffinized with xylene and hydrated through gradient alcohols. Antigen retrieval was achieved by autoclave (170 KPa) in EDTA buffer. Followed that, the slides were treated with a blocking protein (Zhongshan Biotechnology Company, Beijing, China). The sections were incubated with mouse anti-human monoclonal CyclinD1 antibody (1:1000; Zhongshan Biotechnology Company, Beijing, China) overnight at 4°C. An avidin-biotin-peroxidase complex (Dako, Denmark) with DAB as chromogen was used for detecting antibody binding. Secondary antibody was biotinylated anti-rabbit IgG and anti-mouse IgG/IgM (Dako, Denmark) primary antibodies. Representative sections of breast carcinoma served as positive controls for CyclinD1 antibody. We replaced the CyclinD1 with non-immune IgG as negative controls.
Evaluation of immunohistochemical staining
Cyclin D1 staining was evaluated in the glandular epithelium component in each group of simple hyperplasia, atypical complex hyperplasia, and adenocarcinoma. Two parameters were taken into consideration: the intensity of nuclear staining and the extent (percentage of positive cells). Fields for calculating percentage of immune-reactive nuclei were selected based on best tissue preservation and, where there was less artifact, wrinkling or folding. Since the immune-reactivity may not be uniform among nuclei on any given case, we determined grade as the most frequently observed pattern. The intensity of nuclear staining was graded as no staining (0), weak (1+), moderate (2+), or strong (3+). The extent was semi-quantitatively estimated with a range of 0% to 100%. Percentage was estimated by counting at least 50 nuclei and then establishing the ratio of immune-reactive nuclei to total number of nuclei multiplied by 100; percentages were rounded to the nearest 10%. When less than 10% of cells were positive, a score of 0 was used, 10% to 30% cell positivity was scored as 1, 31% to 60% positivity was scored as 2, and more than 60% positive cells was labeled as 3. However, the statistical analysis was based on the data distribution using a continuous range from 1% to 100% reactive cells.
Medical records of these 201 patients from Medical Records Center of Qilu Hospital were checked after getting the approval from Institutional Review Board. Follow-up survey was implemented by telephone calls and clinics to record the survival time of these 201 patients. We adopted Type I censoring, stopping the survey at the predetermined time September, 1st, 2012, at which point any subjects remaining are right-censored. Patients’ death from endometrial diseases were considered as the endpoint event.
Comparison of CyclinD1 expression in different status of the endometrium was assessed by Partitioning Chi-squares and Fisher’s exact test when an expected cell value was 5 or less by PASW Statistics 18.0 software. Survival curves were created from Kaplan-Meier method with the log-rank test. Comparisons were made by Cox’s proportional hazards model regression. Results were presented in the form of hazard ratios (HR) and 95% confidence interval (95CI). A p < 0.05 was considered statistically significant.
Expression of CyclinD1 in endometrial diseases
Expression of CyclinD1 in the tissue of endometrial lesions
Atypical complex hyperplasia
Endometrial serous carcinoma
Clear cell carcinoma
Statistical comparisons of CyclinD1 expression in endometrial lesions
Statistical comparisons of five endometrial lesions
Parameter a vs. Parameter b
Positives (Parameter a)
Positives (Parameter b)
χ 2 value*
Simple hyperplasia vs. atypical complex hyperplasia
Simple hyperplasia vs. endometrioid carcinoma
Simple hyperplasia vs. endometrial serous carcinoma
Simple hyperplasia vs. clear cell carcinoma
Atypical complex hyperplasia vs. endometrioid carcinoma
Atypical complex hyperplasia vs. endometrial serous carcinoma
Atypical complex hyperplasia vs. clear cell carcinoma
Endometrioid carcinoma vs. endometrial serous carcinoma
Endometrioid carcinoma vs. clear cell carcinoma
Endometrial serous carcinoma vs. clear cell carcinoma
Correlation of CyclinD1 expression with the clinic-pathological features of the endometrial lesions
Correlation of CyclinD1 expression with the clinicopathological variables
χ 2 value
Atypical complex hyperplasia
Endometrial serous carcinoma
Clear cell carcinoma
Kaplan-Meier survival curve of the expression CyclinD1 in 201 patients with endometrial diseases
Multivariate Cox regression analysis of CyclinD1 expression and clinic-pathological features
Multivariate cox regression analysis of CyclinD1 expression and clinicopathological variables
95.0%CI for HR
Atypical complex hyperplasia
Endometrial serous carcinoma
Clear cell carcinoma
Tumor is a type of general, systematic and step-by-step developing disease involving a series of factors; it is caused by the mutation of the oncogenes and disorders of some genes. Endometrial carcinoma is a malignant cancer that derives from endometrial glandular epithelium. The formation of organs and tissues of female reproductive tract is through the development, evolvement and differentiation of Miller’s tube. The epithelium of Miller’s tube is characterized by a multiple differentiation potential. After birth, these undifferentiated embryonic cells retained within the germinal layer of tissue in the mature organism. So when cancers happen in the female reproductive tract organs or tissues, not only can they form the same type of cancer tissues with the original tissues, namely endometrial adenocarcinoma, but also they can develop other types of cancers which derive from the multidifferentiation of Miller tubular epithelium. These types of cancers are such as endometrial serous carcinoma, clear cell carcinoma, mucinous adenocarcinoma, squamous cell carcinoma, mixed carcinoma and undifferentiated carcinoma and etc.[14, 15] This situation leads to the complexity and diversity of endometrial diseases.
CCND1, as a proto-oncogene located on chromosome 11q13, has been studied in recent years. CyclinD1, the protein encoded by the gene, is originally proposed by Motokura et al, they found CyclinD1’s over expression in the parathyroid glands. CyclinD1 protein plays an important and positive role during the key rate-limiting point G1 → S phase transition in the cell cycle. It can activate CDK4 or CDK6 to phosphosphorylate a series of key substrates, such as protein Rb, in that case, the transcription factors will be released to promote synthesis of DNA and accelerate the cells proliferation. Thus it is an essential sensor and activator of cell cycle initiation and progression; Cyclin D1 amplification and gain copies with consequent protein over-expression have been frequently described in multiple myeloma, T cutaneous lymphomas and in solid cancer, such as oral squamous cell carcinoma, lung cancer, melanoma, breast cancer[19, 20]. A recent study has shown that strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification.
The results of this research showed the expression of CyclinD1 increased in the order of simple hyperplasia, ACH, endometrioid carcinoma, CCC except ESC, the statistical comparisons of these types with each other demonstrated no statistical significance (P > 0.005). However, the further analysis showed that patients with CyclinD1 expression usually accompanied by lymph node metastasis and poor prognosis (P <0. 05), this is consistent with Nikaido’s report.. Thus, CyclinD1’s over expression is positively correlated with the lymph node metastasis and poor prognosis. As a positive regulator of cell cycle, CyclinD1’s over expression may lead to uncontrolled cell proliferation. Even though its expression rate increased with the level of malignancy of the endometrial lesions, it still lacks the specificity to differentiate non-neoplastic and neoplastic endometrial tissues. Therefore, we could not merely use CyclinD1 as a diagnostic marker when we confront a dilemma of distinguishing non-neoplastic and neoplastic lesions, but its application could predict the prognosis more credibly and accurately. In other words, CyclinD1 could be an applicable indicator for the prognosis of endometrial cancer. Future studies on the role of CyclinD1 of endometrial carcinogenesis are needed.
In conclusion, our study demonstrated that the expression of CyclinD1 was up-regulated with the level of malignancy of the endometrial lesions; it lacks the specificity to differentiate non-neoplastic and neoplastic endometrial tissues. The results showed that the expression of CyclinD1 was tightly correlated with the metastasis of endometrial cancers. The facts above demonstrated that CyclinD1 play an important role in the formation and development of endometrial cancers. Significantly, Kaplan-Meier survival analysis and multivariate Cox regression analysis showed that CyclinD1and lymph node metastases were risk markers of overall survival; they affected the patients’ prognosis. Therefore, the evaluation of CyclinD1 may assist in predicting the prognosis of endometrial carcinoma as a supplement to ER, PR and P53. Such knowledge may help to identify new strategies for endometrial cancer treatment.
The fund of this study was supported by Department of Pathology, Qilu Hospital affiliated to Shandong University.
- Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C, ESMO Guidelines Working Group: Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011, 22 (suppl 6): vi35-vi39.PubMedGoogle Scholar
- Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, Witzens-Harig M, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Jauch A, Goldschmidt H, Houlston RS, Morgan GJ, Hemminki K: The CCND1 c.870G > A polymorphism is a risk factor for t (11;14)(q13;q32) multiple myeloma. Nat Genet. 2013, 45 (5): 522-5. 10.1038/ng.2583.View ArticlePubMedGoogle Scholar
- Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N, Tassies D, Jaffe ES, Montserrat E, Rozman C: PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 1994, 84: 2726-2732.PubMedGoogle Scholar
- Yang WI, Zukerberg LR, Motokura T, Arnold A, Harris NL: Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol. 1994, 145: 86-96.PubMed CentralPubMedGoogle Scholar
- Yu W, Jin FZ, Ying YL, Gui PH: An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas. Diagn Pathol. 2013, 8: 8-10.1186/1746-1596-8-8.View ArticleGoogle Scholar
- Hong A, Davies S, Stevens G, Lee CS: Cyclin D1 overexpression in AIDS-related and classic Kaposi sarcoma. Appl Immunohistochem Mol Morphol. 2004, 12: 26-30.View ArticlePubMedGoogle Scholar
- Horvai AE, Kramer MJ, O’Donnell R: Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med. 2006, 130: 792-798.PubMedGoogle Scholar
- Kim JK, Diehl JA: Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol. 2009, 220: 292-296. 10.1002/jcp.21791.PubMed CentralView ArticlePubMedGoogle Scholar
- Lin L, Hicks D, Xu B, Sigel JE, Bergfeld WF, Montgomery E, Fisher C, Hartke M, Tubbs R, Goldblum JR: Expression profile and molecular genetic regulation of cyclin D1 expression in epithelioid sarcoma. Mod Pathol. 2005, 18: 705-709. 10.1038/modpathol.3800349.View ArticlePubMedGoogle Scholar
- FIGO: Announcements FIGO stages-- 1988 revision. Gynecol Oncol. 1989, 35: 125-7.View ArticleGoogle Scholar
- Kurman RJ, Zaino RJ, Norris HJ: Endometrial Carcinoma. Blaustein’s Pathology of the Female Genital Tract. Edited by: Kurman RJ. 1994, New York: Springer, 439-86. 4View ArticleGoogle Scholar
- Zhou GY, Gao P: The derivative of molecular pathology——the inevitable development track of the pathology. Journal of Shandong University (Health Sciences). 2011, 49: 63-66.Google Scholar
- Christopherson WM, Alberhasky RC, Connelly PJ: Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer. 1982, 49: 1511-23. 10.1002/1097-0142(19820415)49:8<1511::AID-CNCR2820490802>3.0.CO;2-6.View ArticlePubMedGoogle Scholar
- Lauchlan SC: Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med. 1981, 105: 615-8.PubMedGoogle Scholar
- Lauchlan SC: The secondary mullerian system revisited. Int J Gynecol Pathol. 1994, 13 (1): 73-9. 10.1097/00004347-199401000-00009.View ArticlePubMedGoogle Scholar
- Motokura T, Bloom T, Kim HG, Jüppner H, Ruderman JV, Kronenberg HM, Arnold A: A novel cyclin encoded by a bc-l 1-linked candidat e oncogene. Nature. 1991, 350: 512-10.1038/350512a0.View ArticlePubMedGoogle Scholar
- Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993, 7: 812-21. 10.1101/gad.7.5.812.View ArticlePubMedGoogle Scholar
- Aquino G, Franco R, Ronconi F, Anniciello A, Russo L, De Chiara A, Panico L: Peripheral T-cell Lymphoma with Cyclin D1 overexpression: a case report. Diagn Pathol. 2012, 7: 79-10.1186/1746-1596-7-79.PubMed CentralView ArticlePubMedGoogle Scholar
- Sun Y, Luo D, Liao DJ, et al.: CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells. J Carcinog. 2012, 11: 12-10.4103/1477-3163.100401.PubMed CentralView ArticlePubMedGoogle Scholar
- Mao X, Orchard G, Vonderheid EC, Nowell PC, Bagot M, Bensussan A, Russell-Jones R, Young BD, Whittaker SJ: Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. J Invest Dermatol. 2006, 126 (6): 1388-95. 10.1038/sj.jid.5700224.View ArticlePubMedGoogle Scholar
- Dekanić A, Dintinjan RD, Budisavljević I, Pećanić S, Butorac MŽ, Jonjić N: Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification. Diagn Pathol. 2011, 6: 108-10.1186/1746-1596-6-108.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.